Patched Homolog (PTCH1) Gene as a Reliable Marker for Predicting Imatinib Response in Chronic Phase Chronic Myeloid Leukemia Patients in Correlation With Early Response to First-Line of Treatment Imatinib

被引：0

作者：

Rakha, Nahed Moawad ^{[1
]}

Moahmed, Tamer ^{[1
]}

Said, Rasha Magdy M. ^{[1
]}

Ali, Esraa ^{[1
]}

Abdulla, Nour Elhuda ^{[1
]}

机构：

[1] Ain Shams Univ, Internal Med Dept, Clin Hematol Div, Fac Med, Cairo, Egypt

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

CML; PTCH1; chronic phase; patched homolog gene; ELISA; imatinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-024

引用

页码：S331 / S331

页数：1

共 50 条

[1] PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase
Alonso-Dominguez, Juan M.
Felipe Casado, Luis
Anguita, Eduardo
Teresa Gomez-Casares, Maria
Buno, Ismael
Ferrer-Marin, Francisca
Arenas, Alicia
Del Orbe, Rafael
Ayala, Rosa
Llamas, Pilar
Salgado, Rocio N.
Osorio, Santiago
Sanchez-Godoy, Pedro
Burgaleta, Carmen
Mahillo-Fernandez, Ignacio
Garcia-Gutierrez, Valentin
Luis Steegmann, Juan
Martinez-Lopez, Joaquin
PLOS ONE, 2017, 12 (07):
[2] Feasibility Study of Switching to Nilotinib After First-line Imatinib in the Chronic Phase of Chronic Myeloid Leukemia
Chen, Yilin
Yin, Hua
Chen, Lifeng
Xiong, Yingyuan
Meng, Li
Guo, Jingming
Wang, Haiyan
Li, Weiming
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (02) : E43 - E49
[3] Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib
Quintas-Cardama, Alfonso
Jabbour, Elias J.
LEUKEMIA RESEARCH, 2013, 37 (05) : 487 - 495
[4] EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib
Tao, Zhonfei
Liu, Bingcheng
Zhao, Yaozhong
Wang, Ying
Zhang, Rongli
Han, Mingzhe
Zhang, Li
Li, Chengwen
Ru, Kun
Mi, Yingchang
Wang, Jianxiang
LEUKEMIA RESEARCH, 2014, 38 (09) : 1030 - 1035
[5] First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Wei, Guoqing
Rafiyath, Shamudheen
Liu, Delong
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2010, 3
[6] PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase
Alonso-Dominguez, Juan M.
Grinfeld, Jacob
Alikian, Mary
Marin, David
Reid, Alistair
Daghistani, Mustafa
Hedgley, Corinne
O'Brien, Stephen
Clark, Richard E.
Apperley, Jane
Foroni, Letizia
Gerrard, Gareth
AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (01) : 20 - 26
[7] First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Guoqing Wei
Shamudheen Rafiyath
Delong Liu
Journal of Hematology & Oncology, 3
[8] Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
Gemelli, Maria
Elli, Elena Maria
Elena, Chiara
Iurlo, Alessandra
Intermesoli, Tamara
Maffioli, Margherita
Pungolino, Ester
Carraro, Maria Cristina
D'Adda, Mariella
Lunghi, Francesca
Anghileri, Michela
Polverelli, Nicola
Rossi, Marianna
Bacciocchi, Mattia
Bono, Elisa
Bucelli, Cristina
Passamonti, Francesco
Antolini, Laura
Gambacorti-Passerini, Carlo
BLOOD RESEARCH, 2020, 55 (03) : 139 - 145
[9] Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase
Quintas-Cardama, Alfonso
Cortes, Jorge E.
Kantarjian, Hagop M.
CANCER, 2011, 117 (23) : 5261 - 5270
[10] Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia
Nekoohesh, Ladan
Rostami, Shahrbano
Nikbakht, Mohsen
Mohammadi, Saeed
Babakhani, Davood
Alimoghaddam, Kamran
Ghahremani, Mohammad H.
Chahardouli, Bahram
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (01) : E1 - E10

← 1 2 3 4 5 →